PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9407366

Physicians' guide to interactions between glaucoma and systemic medications.

M S Gottfredsdottir·R R Allingham·M B Shields
View original source ↗Export metadata ↓

Abstract

PURPOSE: To develop a Physicians' Guide to assist clinicians in the concomitant use of glaucoma and systemic medications. METHODS: The records of 100 consecutive patients with chronic open-angle glaucoma were retrospectively studied to determine the most common systemic medications that are prescribed in this population. The ten most common drug classes were then used to construct a guide to potential interactions and side effects when these medications are used concomitantly with glaucoma drugs. RESULTS: Eighty-four patients were receiving 1 or more medications (a mean of 3.5) for a mean of 2.6 systemic conditions. Systemic antihypertensive agents was the most common class of drugs, being used by 48 patients. Aspirin, the most common single systemic drug, was being used by 25 patients. CONCLUSIONS: A high percentage of patients with chronic open-angle glaucoma receive a wide variety of medications for coexisting systemic disorders. The concomitant use of glaucoma and systemic medications creates the potential for drug interactions, as well as side effects for both groups of drugs, for which the Physicians' Guide may be beneficial.

Explore related subjects

Adrenergic beta-AntagonistsAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAnticoagulantsAntihypertensive AgentsCarbonic Anhydrase InhibitorsCardiovascular DiseasesChronic DiseaseDiabetes ComplicationsDiabetes MellitusDrug InteractionsFemaleGlaucoma, Open-AngleHormonesHumansHypothyroidismMaleMiddle AgedPractice Guidelines as TopicRetrospective StudiesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M S Gottfredsdottir, R R Allingham, M B Shields. 1997. Physicians' guide to interactions between glaucoma and systemic medications.. https://pubmed.ncbi.nlm.nih.gov/9407366/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Central corticotropin releasing factor (CRF) and adrenergic receptors mediate hemodynamic responses to cocaine.

Cocaine administration evokes cardiovascular responses that are variable in rats such that the pressor response is attributable to either a large increase in systemic vascular resistance and a decrease in cardiac output (vascular responders) or a smaller increase in systemic vascular resistance and no change or an increase in cardiac output (mixed responders). This study was designed to determine the role of central corticotropin releasing factor (CRF) and adrenergic receptors in mediating specific hemodynamic response patterns. Rats were instrumented for ascending aortic blood flow determination (cardiac output) using a pulsed Doppler system, arterial pressure measurement and for intravenous and intracerebroventricular (icv) administration of drugs. After characterizing the hemodynamic response pattern in individual rats to cocaine (5 mg/kg, i.v., 4-6 trials), selective receptor antagonists were administered icv 10 min before cocaine (5 mg/kg, i.v.). Pretreatment with the CRF antagonist alpha-helical CRF(9-41) (10 microg/5 microl, icv) prevented the decrease in cardiac output in vascular responders without altering hemodynamic responses to cocaine in mixed responders. Astressin (5 microg/5 microl, icv) exerted a similar effect in vascular responders. The alpha(2) receptor antagonist, yohimbine (3 microg/microl, icv) also prevented the decrease in cardiac output in vascular responders. Lower doses of alpha-helical CRF(9-41) (1 and 3 microg) were ineffective whereas higher doses of either CRF antagonist were lethal within 24 h. In contrast, propranolol (3 or 30 microg, icv) pretreatment enhanced the cocaine-induced decrease in cardiac output and increase in systemic vascular resistance noted in vascular responders and resulted in a decrease in cardiac output in mixed responders. We conclude that CRF and adrenoceptors in the CNS play an important role in determining the hemodynamic response pattern to cocaine. Furthermore, central beta-adrenoceptors may be responsible for the reported effects of intravenous propranolol on cocaine-induced responses.

Adrenergic beta-Antagonists↗
PubMed2001

Selective beta(1)-blockade improves cardiac bioenergetics and function and decreases neuroendocrine activation in rats during early postinfarct remodeling.

In spite of the solid evidence that beta-blockade reduces mortality and morbidity in congestive heart failure (CHF) this therapy continues to be underused in clinical praxis. The reason for this may lie in scarcity of knowledge about the mechanisms of beta-blockade action. The major aim of this study was to investigate in vivo whether selective beta(1)-blockade may improve cardiac energy metabolism in rats with myocardial infarction in early postinfarct remodeling phase. Myocardial infarction (MI) was induced in male Sprague-Dawley rats by ligation of the left coronary artery. Two different groups of rats were studied, rats with MI treated with metoprolol (5 mg/kg/h; n = 9) and rats with MI saline treated (n = 9). The treatment with metoprolol was given by subcutaneously implanted minipumps and was initiated at 3 days postinfarct and during the period of 4 weeks. All rats were investigated with noninvasive methods (31)P magnetic resonance spectroscopy (MRS) and transthoracic echocardiography 3 days after induction of MI and 4 weeks later. Phosphocreatine/ATP ratio was normalized after the treatment with metoprolol while it was 50% lower in the saline group (p < 0.001). In the metoprolol group stroke volume and ejection fraction increased while deceleration time of mitral early filling was longer (all p < 0.05). Left ventricular weight as well as volumes and dimensions were similar between the groups. Plasma levels of noradrenaline (p = 0.058), adrenaline (p < 0.01) and brain natriuretic peptide (p = 0.09) were lower in the metoprolol group. Selective beta(1)-blockade with high dose of metoprolol initiated in the early postinfarct phase improves myocardial energy metabolism and function and prevents overactivation of sympathetic system. The beneficial effect on myocardial bioenergetics may be an important mode of action of beta-blockers which contributes to the clinical benefits of the therapy in CHF.

Adrenergic beta-Antagonists↗